 When people think about drug shortages, the conversation often centers around hospitals and surgery centers and, rightfully so, the focus is on critical medications and life-saving therapies. But shortages don’t stop there. In ophthalmology, access to sterile, high-quality medications is just as critical, and disruptions can have life-altering consequences for patients whose vision depends on timely treatment.
Across retina practices and ophthalmology clinics, providers face increasing supply instability in both compounded and repackaged ophthalmic medications. From anti-infectives like moxifloxacin to retina therapies such as repackaged bevacizumab (Avastin®), these shortages create significant clinical challenges for physicians and staff working to save and restore their patients’ eyesight. A Market Under Pressure In the fall of 2024, the ophthalmic market experienced a major disruption when a significant supplier exited the repackaged Avastin market suddenly and without notice. For retina specialists who rely on Avastin as a trusted treatment option for conditions such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusions, the impact was immediate. This supply disruption created uncertainty across the market, forcing practices to navigate limited availability, shifting sourcing strategies, and concerns around continuity of care for patients who require ongoing injections to preserve vision. At the same time, the market entered 2026 facing another significant challenge: national shortages of moxifloxacin, a critical ophthalmic anti-infective commonly used in cataract and other surgical procedures. As ophthalmic providers continue to manage high patient volumes and increasing procedural demand, access to sterile, ready-to-use medications remains essential to maintaining both efficiency and patient safety. These shortages highlight a broader truth: ophthalmic supply continuity is not optional; it is foundational to patient care. The Importance of Reliable Partners When shortages occur, physicians need more than a temporary solution. They need a supply partner built for quality, supply reliability, and long-term support. That means investing in:
In ophthalmology, where quality and reliability are non-negotiable, these investments make the difference between temporary access and sustainable continuity. Supporting the Ophthalmic Market Through Supply Reliability At Leiters Health, we recognize that supporting ophthalmology providers means helping physicians protect patient outcomes, not just filling orders. Backed by a century of pharmaceutical heritage, we combine deep industry expertise with state-of-the-art automated manufacturing, rigorous quality standards, and an unwavering commitment to service, setting the standard for reliability and consistency in compounded medications. As a trusted 503B outsourcing facility and provider of compounded and repackaged ophthalmic medications, Leiters Health continues to play a pivotal role in helping stabilize the retina and ophthalmology markets during times of disruption. Through continual investment in quality systems, automation, and a robust inventory strategy, we work to ensure our customers have dependable access to the medications they rely on most for patient care. Our focus is not simply responding to shortages after they happen but using sophisticated AI-driven tools to proactively predict shortages while simultaneously building the infrastructure and operational discipline needed to help prevent supply interruptions before they occur. Whether supporting retina specialists with repackaged Avastin or helping providers navigate ongoing antibiotic shortages, our commitment remains the same: delivering confidence through quality, continuity and the reliable supply needed to support patient care. Looking Ahead Drug shortages across the ophthalmology landscape are a reminder that preserving vision requires more than clinical excellence; it requires a pharmaceutical supply chain strong enough to ensure it. It also requires an ongoing investment in the future, advancing quality systems, expanding automation, strengthening inventory strategies, and building the infrastructure needed to meet evolving patient and provider needs. By staying focused on the next step, we can help ensure consistent access to the medications that support physicians and patient care. Because when it comes to vision, delays are not just inconvenient, they can be permanent. To learn more about how Leiters Health can help stabilize your pharmaceutical supply chain with our hospital and ophthalmic compounded and repackaged medications please visit leiters.com Comments are closed.
|
